<p>1. Develop new ultra sensitive immunodiagnostic assays for biological toxins and validate using standard animal bioassays.</p><p>2. Develop new detection or diagnostic technologies.</p><p> 3. Use this new technology to determine the toxicokinetics of toxins in animals.</p>
<p>SpinDx, a novel microflulidic diagnostic platform, will be used in the detection of high consequence pathogens and toxins. ARS developed monoclonal antibodies will be used in the immuno-detection of botulinum neurotoxins (BoNT) and other biological toxins. This new approach will be tested for efficacy and sensitivity in the "gold standard" mouse bioassays for toxin detection, as well as in ELISA detection formats. The collaborator will generate a prototype of the detector. ARS will test the prototype assay/instrument with spiked food samples and also with samples from mice intoxicated with toxins. We will compare the new assays using the prototype against gold standard assays, including the mouse BoNT assay or ELISA.</p>